◆ TICKERBASE · GLOBAL STOCK FINANCIAL DATA LIBRARY

JBM (Healthcare) Limited (2161) Financial History

Name: JBM (Healthcare) Limited (2161) financial statement history
Creator: TickerBase
License: https://creativecommons.org/licenses/by/4.0/

4 years of revenue, earnings, cash-flow and balance-sheet history from public filings.

Healthcare · Drug Manufacturers - Specialty & Generic · DATA UPDATED 2026-09-22

JBM (Healthcare) Limited (2161) operates in the Drug Manufacturers - Specialty & Generic industry and is headquartered in Kwun Tong, Hong Kong with about 404 employees. Its market capitalization is roughly HK$1 billion. In the fiscal year ended 2026-03-31, 2161 reported HK$835M in revenue and HK$201M in net income.

JBM (Healthcare) Limited, an investment holding company, engages in the manufacture, marketing, distribution, and sale of branded healthcare and wellness products in Hong Kong, Macau, Mainland China, Singapore, and internationally.

Interactive charts & full statements → Open the 2161 valuation workbench →

2161 Revenue & Earnings History — Annual Income Statement

Income statement	2026-03-31	2025-03-31	2024-03-31	2023-03-31	2022-03-31
Total Revenue	HK$835M	HK$782M	HK$648M	HK$520M	—
Gross Profit	HK$466M	HK$414M	HK$338M	HK$206M	—
Operating Income (EBIT)	HK$255M	HK$229M	HK$158M	HK$73M	—
Net Income	HK$201M	HK$197M	HK$130M	HK$57M	—

HKD; HK$M / HK$B as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).

2161 Free Cash Flow History

Cash flow	2026-03-31	2025-03-31	2024-03-31	2023-03-31	2022-03-31
Dividends Paid	(HK$174M)	(HK$79M)	(HK$53M)	(HK$4M)	—

HKD; HK$M / HK$B as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).

2161 Balance Sheet History

Balance sheet	2026-03-31	2025-03-31	2024-03-31	2023-03-31	2022-03-31
Total Assets	HK$1.8B	HK$1.5B	HK$1.4B	HK$1.4B	—
Total Liabilities	HK$632M	HK$381M	HK$367M	HK$372M	—

HKD; HK$M / HK$B as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).

Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive 2161 viewer.

Other Companies in Drug Manufacturers - Specialty & Generic

BALPHARMA · Bal Pharma Limited — ₹2 billion
2348 · Dawnrays Pharmaceutical (Holdings) Limited — HK$1 billion
PPGN · PolyPeptide Group AG — CHF 1 billion
6896 · Golden Throat Holdings Group Company Limited — HK$1 billion
KREBSBIO · Krebs Biochemicals & Industries Limited — ₹1 billion
1061 · Essex Bio-Technology Limited — HK$1 billion
BALAXI · Balaxi Pharmaceuticals Limited — ₹1 billion
ALPA · Alpa Laboratories Limited — ₹1 billion

← 2160 All “0-9” companies 2162 →

About TickerBase · Data methodology & sources · Privacy · Terms

TickerBase is provided for educational and informational purposes only. It does not constitute financial, investment, tax, or legal advice, or a recommendation to buy, sell, or hold any security. No price targets are published; any per-share value shown in the valuation workbench is generated entirely from reader-supplied assumptions and is not the publisher's view of fair value. Past performance does not predict future results. Figures are approximate and drawn from public filings; one-time items are noted where identified. Do your own research and consult a licensed professional before making any investment decision. The author may or may not hold positions in the securities discussed.